CD73 anticorps (full length) (Biotin)

N° du produit ABIN7877582

Cet anticorps Souris Monoclonal détecte spécifiquement CD73 dans WB, FACS, IF, ELISA et IHC (p). Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour CD73 anticorps (full length) (Biotin) (ABIN7877582)

Antigène: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD73 est conjugé à/à la Biotin

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: NT5E-2646

Détail du produit anti-CD73 anticorps (Biotin)

Épitope: full length

Fonction: CD73 Antibody

Purification: Protein G affinity chromatography

Immunogène: Recombinant full-length human NT5E protein was used as the immunogen for the CD73 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the CD73 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 0.1 mg/mL with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store the CD73 antibody at 2-8oC (up to one month) or aliquot and store at -20oC (longer term).

Détails sur CD73

Antigène: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Autre désignation: CD73

Sujet: CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.

UniProt: P21589

Pathways: Synaptic Membrane, Ribonucleoside Biosynthetic Process